The Effect of Simvastatin on Desensitization of Panel-Positive Kidney Transplant Candidates
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||The Effect of Simvastatin on Desensitization of Panel-Positive Kidney Transplant Candidates|
- effect of simvastatin on panel reactive antibody [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
|Study Start Date:||April 2007|
|Study Completion Date:||May 2008|
|Primary Completion Date:||May 2008 (Final data collection date for primary outcome measure)|
patients who will take simvastatin 20 mg daily
20 mg simvastatin daily
The presence of panel reactive antibodies (PRAs) in the sera of renal transplant candidates is associated with hyperacute or delayed humoral immune responses against the graft after transplantation .
In addition, these sensitized patients wait for a long time to find a cross-match negative kidney for renal transplantation . As a result, some modalities have been used for desensitization including plasmapheresis and intravenous immunoglobulin (IVIG) in combination with immunosuppressive drugs .
However, recently, the use of statins such as simvastatin, pravastatin and etc. has been proposed to be safer and more effective for desensitization .
Please refer to this study by its ClinicalTrials.gov identifier: NCT00693576
|Iran, Islamic Republic of|
|Shiraz University of Medical Sciences|
|Shiraz, Fars, Iran, Islamic Republic of, 71937-11351|
|Study Director:||jamshid roozbeh, associate professor||shiraz university of medical science|
|Principal Investigator:||azar Sattarinezhad, internal medicine resident||shiraz university of medical science,internal medicine department|
|Principal Investigator:||mohammad mahdi sagheb, assistant professor||Shiraz University of Medical Sciences|